Table 1. Patient's characteristics at baseline (n=20).
| Age (years)–mean (range) | 69 | (54–84) |
|---|---|---|
|
Initial treatment, n (%) | ||
| Curative intention | 9 | (45) |
| Primary ADT |
11 |
(55) |
|
ADT method, n (%) | ||
| Bilateral orchiectomy | 9 | (45) |
| LHRH agonists |
11 |
(55) |
|
Second-line treatment, n (%) | ||
| Oestrogens | 15 | (75) |
| Ketoconazol plus prednisone | 1 | (5) |
| Chemotherapy |
1 |
(5) |
|
Duration of ADT, months (range) |
24,5 |
(6–81) |
|
Metastases, n (%) | ||
| Bone | 14 | (70) |
| Lymph node | 14 | (70) |
| Visceral | 0 | (0) |
| None |
6 |
(30) |
|
Progression, n (%) | ||
| Biochemical | 13 | (65) |
| Metastases |
7 |
(35) |
| Patients that completed treatment protocol, n (%) | 14 | (70) |
Abbreviations: ADT=androgen deprivation therapy; LHRH=luteinizing hormone-releasing hormone.